Evidence map›Paper›PMID 39207720›Full record

ArticleJournal of hematopathology2024

Systemic ALK-negative anaplastic large cell lymphoma with NPM1::TYK2 rearrangement.

Mckinzie Johnson, Nicholas Willard, Zenggang Pan

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of hematopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mckinzie JohnsonDepartment of Pathology, University of Colorado Hospital, University of Colorado School of Medicine, 12605 East 16 Avenue, Aurora, CO, 80045, USA.
Nicholas WillardDepartment of Pathology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Zenggang PanDepartment of Pathology, University of Colorado Hospital, University of Colorado School of Medicine, 12605 East 16 Avenue, Aurora, CO, 80045, USA. zenggang.pan@cuanschutz.edu.ORCID http://orcid.org/0000-0003-4537-3356

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic large cell lymphoma (ALCL) is a rare subtype of non-Hodgkin lymphoma, with most cases harboring ALK gene rearrangement (ALK + ALCL); however, 20-50% of ALCLs do not have the rearrangement (ALK- ALCL) but exhibit distinct genetic alterations. In this report, we present an unusual case of systemic ALK- ALCL with NPM1::TYK2 fusion. Diagnosis of this case was challenging prior to the NGS findings. A comprehensive panel of immunohistochemical and in-situ hybridization studies was conducted. FISH assays were utilized to target the rearrangements of DUSP22 and TP63 genes. Moreover, next-generation sequencing (NGS) assays were performed to detect clonal rearrangements of IGH and TRG genes, somatic mutations, and potential fusions. The lymphoma cells in this case are negative for all hematolymphoid markers stained, except for CD30 expression and focal and weak CD43 expression. However, NGS studies detected clonal TRG rearrangement and NPM1::TYK2 rearrangement, which aid in the diagnosis of ALK- ALCL. NPM1::TYK2 rearrangement is a rare genetic alteration that has been reported in rare cases of primary cutaneous ALCL, mycosis fungoides, and lymphomatoid papulosis. To the best of our knowledge, this is the first reported instance of such rearrangement in systemic ALK- ALCL.

Indexed as

Gene RearrangementLymphoma, Large-Cell, AnaplasticNuclear ProteinsNucleophosminAnaplastic Lymphoma KinaseFemaleHumansMaleOncogene Proteins, FusionALK protein, humanAnaplastic Lymphoma KinaseNPM1 protein, humanNuclear ProteinsNucleophosminOncogene Proteins, FusionALCLALK-negativeAnaplastic large cell lymphomaNPM1::TYK2 rearrangementTYK2 rearrangement

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.